Evogene Valuation

EVGN Stock  USD 1.43  0.05  3.62%   
Based on Macroaxis valuation methodology, the firm appears to be undervalued. Evogene shows a prevailing Real Value of $3.12 per share. The current price of the firm is $1.43. Our model computes the value of Evogene from reviewing the firm fundamentals such as Current Valuation of 6.96 M, shares outstanding of 6.8 M, and Profit Margin of (1.94) % as well as analyzing its technical indicators and probability of bankruptcy.
Undervalued
Today
1.43
Please note that Evogene's price fluctuation is very risky at this time. Calculation of the real value of Evogene is based on 3 months time horizon. Increasing Evogene's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Evogene is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Evogene Stock. However, Evogene's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value.
Historical Market  1.43 Real  3.12 Hype  1.4 Naive  1.41
The intrinsic value of Evogene's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Evogene's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
3.12
Real Value
8.10
Upside
Estimating the potential upside or downside of Evogene helps investors to forecast how Evogene stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Evogene more accurately as focusing exclusively on Evogene's fundamentals will not take into account other important factors:
Bollinger
Band Projection (param)
LowerMiddle BandUpper
1.351.421.50
Details
Hype
Prediction
LowEstimatedHigh
0.071.406.38
Details
Naive
Forecast
LowNext ValueHigh
0.031.416.40
Details

Evogene Total Value Analysis

Evogene is currently forecasted to have valuation of 6.96 M with market capitalization of 9.72 M, debt of 11.51 M, and cash on hands of 35.25 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Evogene fundamentals before making equity appraisal based on enterprise value of the company
  Takeover PriceMarket CapDebt ObligationsCash
6.96 M
9.72 M
11.51 M
35.25 M

Evogene Investor Information

The company recorded a loss per share of 2.89. Evogene had not issued any dividends in recent years. The entity had 1:10 split on the 25th of July 2024. Based on the measurements of operating efficiency obtained from Evogene's historical financial statements, Evogene is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April.

Evogene Asset Utilization

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Evogene has an asset utilization ratio of 11.04 percent. This suggests that the Company is making $0.11 for each dollar of assets. An increasing asset utilization means that Evogene is more efficient with each dollar of assets it utilizes for everyday operations.

Evogene Ownership Allocation

Roughly 90.77 percent of Evogene outstanding shares are held by general public with 1.56 (percent) owned by insiders and only 7.67 % by other corporate entities.

Evogene Profitability Analysis

The company reported the previous year's revenue of 5.64 M. Net Loss for the year was (25.95 M) with profit before overhead, payroll, taxes, and interest of 5.83 M.

About Evogene Valuation

We use absolute and relative valuation methodologies to arrive at the intrinsic value of Evogene. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Evogene based exclusively on its fundamental and basic technical indicators. By analyzing Evogene's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Evogene's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Evogene. We calculate exposure to Evogene's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Evogene's related companies.
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel. Evogene operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 133 people.

Evogene Growth Indicators

Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
Common Stock Shares Outstanding4.6 M
When determining whether Evogene offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Evogene's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Evogene Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Evogene Stock:
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evogene. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.
To learn how to invest in Evogene Stock, please use our How to Invest in Evogene guide.
You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Evogene. If investors know Evogene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Evogene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Evogene is measured differently than its book value, which is the value of Evogene that is recorded on the company's balance sheet. Investors also form their own opinion of Evogene's value that differs from its market value or its book value, called intrinsic value, which is Evogene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Evogene's market value can be influenced by many factors that don't directly affect Evogene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Evogene's value and its price as these two are different measures arrived at by different means. Investors typically determine if Evogene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Evogene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.